Portfolio
AndzonBio1 is developing a pipeline of First-In-Class therapeutics aiming to enter IND-enabling studies by 2028
Programs
Target
Modality
Indications
Discovery
Hit-to-Lead
Lead Opt
IND-enabling
Clinical
Partners
Undisclosed
NCE
Hypertrophic
Cardiomyopathy
Undisclosed
NCE
Liver fibrosis,
immuno-modulation
Undisclosed
Ab
Post-ischemic
cardiac fibrosis
current
Q4 2027
Q4 2028
Programs
Contact
10, rue d’Oradour-sur-Glane
75015 Paris
Contact us for any questions:
contact@andzonbio1.com